EA200870141A1 - Комбинационная терапия с использованием антител к egfr и her2 - Google Patents
Комбинационная терапия с использованием антител к egfr и her2Info
- Publication number
- EA200870141A1 EA200870141A1 EA200870141A EA200870141A EA200870141A1 EA 200870141 A1 EA200870141 A1 EA 200870141A1 EA 200870141 A EA200870141 A EA 200870141A EA 200870141 A EA200870141 A EA 200870141A EA 200870141 A1 EA200870141 A1 EA 200870141A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- her2
- antibodies
- egfr
- cancer
- receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к комбинированному применению антител к EGFR и антител к HER2 для лечения рака, особенно подходящему для рака, экспрессирующего высокие уровни EGFR и низкие уровни HER2. Изобретение имеет отношение, в частности, к моноклональным антителам «trastuzumab» (HERCEPTIN®), нацеленным на рецепторы HER2, эффективность которых может быть значительно повышена in vivo путём комбинирования с моноклональными антителами «matuzumab» (hmAb 425, EMD 72000), нацеленными на рецепторы EGF. Комбинационное лечение пригодно для пациентов, страдающих раком, имеющим указанные характеристики экспрессии рецепторов, предпочтительно раком поджелудочной железы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06000107 | 2006-01-04 | ||
PCT/EP2006/012133 WO2007076923A1 (en) | 2006-01-04 | 2006-12-15 | Combination therapy using anti-egfr and anti-her2 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200870141A1 true EA200870141A1 (ru) | 2009-02-27 |
EA015173B1 EA015173B1 (ru) | 2011-06-30 |
Family
ID=37876938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200870141A EA015173B1 (ru) | 2006-01-04 | 2006-12-15 | Комбинированная терапия с использованием антител к egfr и her2 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20090214541A1 (ru) |
EP (1) | EP1968633B2 (ru) |
JP (1) | JP2009522316A (ru) |
KR (1) | KR20080110987A (ru) |
CN (1) | CN101365486B (ru) |
AR (1) | AR059127A1 (ru) |
AU (1) | AU2006332212B8 (ru) |
BR (1) | BRPI0620888A2 (ru) |
CA (1) | CA2636074A1 (ru) |
EA (1) | EA015173B1 (ru) |
MX (1) | MX2008008564A (ru) |
WO (1) | WO2007076923A1 (ru) |
ZA (1) | ZA200806723B (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
DE60234094D1 (de) | 2001-05-11 | 2009-12-03 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
MX2009007987A (es) | 2007-01-25 | 2010-03-01 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
MX2009009782A (es) | 2007-03-15 | 2010-09-10 | Ludwig Inst Cancer Res | Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas. |
WO2009023265A1 (en) | 2007-08-14 | 2009-02-19 | Ludwig Institute For Cancer Research | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
NZ586544A (en) * | 2007-12-26 | 2012-07-27 | Vaccinex Inc | Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods |
EP2324061B1 (en) | 2008-09-03 | 2017-04-12 | F. Hoffmann-La Roche AG | Multispecific antibodies |
EP2337800B1 (en) | 2008-09-15 | 2013-10-02 | Yeda Research and Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
WO2010120514A2 (en) * | 2009-03-31 | 2010-10-21 | The Trustees Of The University Of Pennsylvania | Antigen-binding proteins comprising recombinant protein scaffolds |
CA2781682A1 (en) * | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
EP2710038B1 (en) | 2011-05-16 | 2018-01-17 | Yeda Research and Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
EP2844675B1 (en) | 2012-05-02 | 2019-01-02 | Symphogen A/S | Humanized pan-her antibody compositions |
US10562974B2 (en) | 2013-03-13 | 2020-02-18 | University Of Kentucky Research Foundation | Methods of administering IgG1 antibodies and methods of suppressing angiogenesis |
WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
EP3693397B1 (en) * | 2013-07-11 | 2024-06-12 | The Scripps Research Institute | Coiled coil immunoglobulin fusion proteins and compositions thereof |
MX2016006301A (es) | 2013-11-13 | 2016-12-16 | Zymeworks Inc | Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos. |
MY193723A (en) * | 2014-08-29 | 2022-10-27 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
CN104991065B (zh) * | 2015-07-07 | 2017-01-11 | 复旦大学附属金山医院 | 一种用于诊断乳腺癌的三联标志物及其应用 |
JP2018062980A (ja) * | 2016-10-12 | 2018-04-19 | 株式会社ジェイテクト | ボールネジ装置、ボールネジ装置の製造方法及びステアリング装置 |
US20180221481A1 (en) * | 2016-12-28 | 2018-08-09 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
CN117915950A (zh) * | 2021-08-06 | 2024-04-19 | 甘李药业股份有限公司 | 一种多特异性抗体及其用途 |
CN117430707B (zh) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | 一种cik细胞的制备方法及其在治疗癌症中的用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
HU219537B (hu) | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
MXPA05003795A (es) * | 2002-10-10 | 2005-06-08 | Merck Patent Gmbh | Composiciones farmaceuticas dirigidas a receptores erb-b1. |
CN1953768B (zh) * | 2004-02-12 | 2010-10-13 | 默克专利有限公司 | 抗-egfr抗体的高浓缩液体制剂 |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
-
2006
- 2006-12-15 JP JP2008548941A patent/JP2009522316A/ja active Pending
- 2006-12-15 KR KR1020087019157A patent/KR20080110987A/ko not_active Application Discontinuation
- 2006-12-15 CN CN2006800503998A patent/CN101365486B/zh not_active Expired - Fee Related
- 2006-12-15 CA CA002636074A patent/CA2636074A1/en not_active Abandoned
- 2006-12-15 AU AU2006332212A patent/AU2006332212B8/en not_active Ceased
- 2006-12-15 BR BRPI0620888-6A patent/BRPI0620888A2/pt not_active IP Right Cessation
- 2006-12-15 US US12/086,725 patent/US20090214541A1/en not_active Abandoned
- 2006-12-15 EA EA200870141A patent/EA015173B1/ru not_active IP Right Cessation
- 2006-12-15 WO PCT/EP2006/012133 patent/WO2007076923A1/en active Application Filing
- 2006-12-15 EP EP06829664.9A patent/EP1968633B2/en not_active Not-in-force
- 2006-12-15 MX MX2008008564A patent/MX2008008564A/es not_active Application Discontinuation
-
2007
- 2007-01-03 AR ARP070100020A patent/AR059127A1/es unknown
-
2008
- 2008-08-01 ZA ZA200806723A patent/ZA200806723B/xx unknown
-
2014
- 2014-11-10 US US14/536,854 patent/US9522956B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI0620888A2 (pt) | 2011-11-29 |
AR059127A1 (es) | 2008-03-12 |
EP1968633B2 (en) | 2017-11-01 |
AU2006332212A1 (en) | 2007-07-12 |
ZA200806723B (en) | 2009-09-30 |
CN101365486B (zh) | 2012-10-31 |
WO2007076923A1 (en) | 2007-07-12 |
US20150132308A1 (en) | 2015-05-14 |
EA015173B1 (ru) | 2011-06-30 |
US20090214541A1 (en) | 2009-08-27 |
AU2006332212B2 (en) | 2013-03-28 |
EP1968633A1 (en) | 2008-09-17 |
AU2006332212B8 (en) | 2013-05-30 |
CA2636074A1 (en) | 2007-07-12 |
MX2008008564A (es) | 2009-01-29 |
EP1968633B1 (en) | 2014-02-12 |
KR20080110987A (ko) | 2008-12-22 |
US9522956B2 (en) | 2016-12-20 |
JP2009522316A (ja) | 2009-06-11 |
CN101365486A (zh) | 2009-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200870141A1 (ru) | Комбинационная терапия с использованием антител к egfr и her2 | |
UA94899C2 (ru) | Фиксированное дозирование антител к her | |
UA94452C2 (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
GEP20135917B (en) | Stabilized polypeptide compositions | |
EA200970335A1 (ru) | Композиции и способы для диагностики и лечения рака | |
MY150756A (en) | Tumor theraphy with an anti-vegf antibody | |
HK1243943A1 (zh) | 使用抗IL-1α抗體治療癌症 | |
RU2012138703A (ru) | Терапевтические и диагностические способы с применением анти-cd200 антител | |
TN2010000210A1 (en) | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same | |
UA92504C2 (en) | Anti-myostatin monoclonal antibody | |
EA201100923A1 (ru) | Антитела человека против тканевого фактора | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
MX358728B (es) | Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados. | |
MY155603A (en) | Notch-binding agents and antagonists and methods of use thereof | |
EA200702053A1 (ru) | Антитела против cd38 для лечения множественной миеломы | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
IL187594A0 (en) | Humanized anti-cd40 antibodies and their methods of use | |
MX2012004084A (es) | Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea. | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
WO2010022736A3 (en) | Recombinant anti-epidermal growth factor receptor antibody compositions | |
NZ604003A (en) | Monoclonal antibodies against her2 | |
MY160892A (en) | Antibodies to ccr2 | |
ATE557042T1 (de) | Anti-myostatin-antikörper | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
NZ611269A (en) | Neutralizing anti-ccl20 antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |